Praxis Medical Insights

Est. 2024 • Clinical Guidelines Distilled

Made possible by volunteer editors from the University of Calgary & University of Alberta

Last Updated: 9/4/2025

High Thrombotic Risk Patient Identification

  • Patients with a history of immobility, cancer, previous thromboembolism, and specific genetic or acquired thrombophilias are at high risk of thrombosis, according to the International Journal of Stroke guidelines 1, 2
  • Patients unable to move one or both lower limbs are at high risk of thrombosis, as stated by the International Journal of Stroke 1, 2
  • Patients with previous history of venous thromboembolism are at high risk of thrombosis, as reported by the International Journal of Stroke 1, 2
  • Dehydration is a risk factor for thrombosis, as noted by the International Journal of Stroke 1, 2
  • Comorbidities such as cancer increase the risk of thrombosis, as stated by the International Journal of Stroke and the Journal of the National Comprehensive Cancer Network 1, 2, 3
  • Patients with advanced disease of the brain, lung, uterus, bladder, pancreas, stomach, and kidney have the highest 1-year incidence rate of venous thromboembolism (VTE), as reported by the Journal of the National Comprehensive Cancer Network and Annals of Oncology 3, 4
  • Metastatic disease increases VTE risk 4-13 times compared to localized disease, according to Annals of Oncology 4
  • The Khorana score identifies high-risk ambulatory cancer patients based on cancer site, pre-chemotherapy platelet count, hemoglobin, leukocyte count, and BMI, as stated by Annals of Oncology 4
  • High-risk patients (score ≥3) have a 6.7% incidence of VTE, as reported by Annals of Oncology 4
  • For multiple myeloma patients receiving immunomodulatory drugs, specific risk assessment models (SAVED or IMPEDE VTE) are recommended by the Journal of the National Comprehensive Cancer Network 5

Genetic and Acquired Thrombophilias

  • Factor V Leiden mutation is the most common genetic cause of thrombophilia, as stated by Stroke 6, 7
  • Prothrombin G20210A mutation is the second most common genetic cause of thrombophilia, according to Stroke 6, 7
  • Antiphospholipid syndrome is the most common acquired cause of thrombophilia, as reported by Stroke 6, 7
  • Deficiencies of coagulation inhibitors (antithrombin III, protein C, or protein S) increase the risk of thrombosis, as noted by Stroke 6, 7
  • Homozygous factor V Leiden carriers have significantly higher risk than heterozygous carriers, as stated by Stroke 6, 7

Cardiovascular and Cerebrovascular Risk Factors

  • Patients with mechanical heart valves, especially older caged-ball valves, are at high risk of thrombosis, as reported by Blood 8
  • Patients with non-valvular atrial fibrillation with high CHADS₂ scores (5-6) are at high risk of thrombosis, according to Blood 8
  • Patients with suspected cardioembolic stroke mechanism are at high risk of thrombosis, as stated by the International Journal of Stroke 1, 9
  • Patients with patent foramen ovale and cryptogenic stroke have an increased risk of paradoxical embolism, as noted by Stroke 6, 7

Perioperative and Procedural Risk

  • Major surgery and laparoscopic procedures with pneumoperitoneum and reverse Trendelenburg position increase the risk of thrombosis, as reported by Blood 8
  • Major cardiovascular surgery, orthopedic surgery, head and neck cancer surgery, and urologic surgery increase the risk of thrombosis, according to Blood 8
  • Surgeries lasting ≥45 minutes increase the risk of thrombosis, as stated by Blood 8

Special Populations

  • Patients with myeloproliferative neoplasms, particularly polycythemia vera, have a high prevalence of thrombosis, as reported by the Journal of the National Comprehensive Cancer Network 5

Risk Stratification Approach

  • For stroke patients, assessing mobility status, previous VTE history, and comorbidities is recommended by the International Journal of Stroke 1, 2
  • For cancer patients, using validated risk assessment models (Khorana score, SAVED, IMPEDE VTE) is recommended by Annals of Oncology and the Journal of the National Comprehensive Cancer Network 4, 5
  • For surgical patients, considering procedure type, duration, and patient-specific factors is recommended by Blood 8
  • For patients with atrial fibrillation, using the CHADS₂ score is recommended by Blood 8

Important Caveats

  • Genetic screening for thrombophilia is not recommended for primary prevention in asymptomatic individuals, as stated by Stroke and the Journal of the National Comprehensive Cancer Network is not the primary source, but Stroke is 6, 7, 10

REFERENCES

3

update on guidelines for the prevention of cancer-associated thrombosis. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2022

5

update on guidelines for the prevention of cancer-associated thrombosis. [LINK]

Journal of the National Comprehensive Cancer Network : JNCCN, 2022

10

Treatment Recommendations for Prothrombin 2 (PT20210) Mutation [LINK]

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025